Ones To Watch News
Refine Search
Biotechnology
İş Private Equity - a subsidiary of Turkey's İşbank Group - has committed $39 million to a Harvard University research lab to launch Enlila, a biotech developing novel treatments for metabolic diseases. 20 June 2025
Pharmaceutical
Privately-held UK firm Cycle Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Harliku (nitisinone) tablets for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria (AKU). 20 June 2025
Pharmaceutical
Zealand Pharma, a Danish firm focused on the discovery and development of innovative peptide-based medicines, has announced positive topline results from part two of a Phase Ib multiple ascending dose (MAD) trial investigating 28 weeks of treatment with dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist. 20 June 2025
Biotechnology
Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies. 19 June 2025
Biotechnology
Scholar Rock has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug can reduce the amount of lean mass lost during weight reduction with Eli Lilly’s (NYSE: LLY) weight-loss drug Zepbound (tirzepatide). 19 June 2025
Pharmaceutical
Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership shake-up timed with a fresh $25 million financing round and a push to commercialize its lead eye implant therapy in the USA. 19 June 2025
Pharmaceutical
US biotech Actio Biosciences has raised $66 million in a series B round topport its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management. 19 June 2025
Biotechnology
SunRock Biopharma has teamed up with China’s Escugen to co-develop SRB123, a first-in-class antibody-drug conjugate (ADC) targeting CCR9, an antigen which is tied to particularly hard-to-treat cancers, including pancreatic, ovarian and lung. 18 June 2025
Biotechnology
Chinese biotech start-up BioTroy Therapeutics has raised over 200 million renminbi ($28 million) in series A financing to advance clinical trials for its experimental immunotherapy targeting CD3L1, a novel immune checkpoint aimed at tough-to-treat tumors. The company also plans to expand its early-stage pipeline and grow its Shanghai-based R&D team. 18 June 2025
Pharmaceutical
US biopharma Mineralys Therapeutics has announced positive top-line data from its Phase II Explore-CKD trial evaluating the safety and efficacy of 25mg of lorundrostat in subjects with hypertension and comorbid chronic kidney disease (CKD). 18 June 2025
Biotechnology
Cambridge, USA-based Immuneering Corporation late yesterday announced positive data from its ongoing Phase IIa clinical trial evaluating atebimetinib (IMM-1-104), an oral, once-daily novel MEK inhibitor, in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients. 18 June 2025
Pharmaceutical
Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric diseases, today launched from stealth having raised a total of $140 million (£107 million) in the last nine months. 18 June 2025
Pharmaceutical
US pharma firm Lisata Therapeutics has teamed up with tech-bio company GATC Health in a strategic alliance aimed at using artificial intelligence to streamline drug development and improve success rates. 18 June 2025
Biotechnology
US biotech Dyne Therapeutics has revised its regulatory approach for DYNE-101, a treatment in development for myotonic dystrophy type 1 (DM1), after discussions with the American medicines regulator. 18 June 2025
Biotechnology
Shares of USA-based NextCure slumped 26% to $0.50 on Monday, after the company announced a strategic partnership with China-based Simcere Zaiming, subsidiary of Simcere Pharmaceutical Group Ltd to develop a therapy for the treatment of solid tumors. 17 June 2025
Biotechnology
Cambridge, UK-based Maxion Therapeutics today announced the appointment of Dr Stefan Härtle as chief development officer, effective immediately. 17 June 2025
Pharmaceutical
Supernus Pharmaceuticals is to buy Sage Therapeutics for total consideration of around $795 million. 16 June 2025
Pharmaceutical
French drug developer Averoa today announced that the European Commission (EC) has granted marketing authorization for Xoanacyl (ferric citrate coordination complex). 16 June 2025
Biotechnology
Boston, USA-based biotech Solu Therapeutics today announced the appointment of Enda Moran as chief operating officer (COO). 16 June 2025
Biotechnology
Californian biotech Jasper Therapeutics presented data from the 180mg cohort of the company’s SPOTLIGHT Phase Ib/IIa study of subcutaneous briquilimab in adult participants with chronic inducible urticaria (CIndU) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. 16 June 2025
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Biotechnology
Boston, USA-based Seaport Therapeutics has announced the closing of an oversubscribed $225 million Series B financing round, adding to the $100 million it pulled in along with its launch in April. 21 October 2024
Pharmaceutical
Sweden-based OncoZenge has announced the intention to partner with UK-based specialty pharma Pharmanovia to secure exclusive rights to commercialize BupiZenge in Europe, the Middle East, and Northern Africa (EMENA). 21 October 2024
Pharmaceutical
Angelini Pharma, part of Italy’s Angelini Industries, has entered into an exclusive option agreement with South Korea-based Cureverse for the global development and commercialization of a clinical-stage brain health asset. 21 October 2024
Biotechnology
LaNova Medicines, a Shanghai-based biopharma company, has announced that it has secured 3 billion yuan ($41 million) in its series C funding round. 18 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Pharmaceutical
US biotech company Sage Therapeutics is to slash a third of its remaining jobs - just a year after cutting 40% of its prior workforce. 18 October 2024
Biotechnology
California, USA-based biotech Terray Therapeutics, yesterday announced the closing of an oversubscribed Series B funding of $120 million. 18 October 2024
Pharmaceutical
British artificial intelligence specialist BenevolentAI has announced the return of its founder, Ken Mulvany, as executive chairman. 18 October 2024
Biotechnology
RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of a collaboration and license agreement that the companies signed in 2018. 17 October 2024
Biotechnology
US RNA medicines biotech Wave Life Sciences yesterday announced positive proof-of-mechanism data from the ongoing Phase Ib/IIa RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD) 17 October 2024
Pharmaceutical
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Biotechnology
In Cambridge, UK, the protein specialist Nuclera has raised $75 million in a funding round led by Elevage Medical Technologies and backed by Patient Square Capital. 16 October 2024
Biotechnology
TRIANA Biomedicines has entered into a strategic collaboration and licensing agreement with US pharma giant Pfizer to discover novel molecular glue degraders for multiple targets in several disease areas, including oncology. 16 October 2024
Biotechnology
Tolerance Bio has announced the closing of its oversubscribed $17.2 million seed financing round, led by Columbus Venture Partners. 16 October 2024
Biotechnology
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
Biotechnology
US clinical-stage genetic meds company MeiraGTx Holdings has released positive top-line data from its clinical bridging study of AAV-GAD for the treatment of Parkinson’s disease, MGT-GAD-025. 15 October 2024
Biotechnology
In Hong Kong, Akeso Biopharma has successfully raised $250 million through a share placement, marking its second major fundraising effort of 2024. 15 October 2024
Pharmaceutical
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
Pharmaceutical
Canada-based biotech Sernova (TSX: SVA) has announced key new appointments to its executive leadership team. 15 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze